A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes

Yanagi, Kazunori; Monden, Tsuyoshi; Ikeda, Shiori; Matsumura, Mihoko; Kasai, Kikuo

doi:10.1007/s12325-010-0098-2

Cited by 17 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,27 It was concluded, however, that conventional statin therapy should not be changed, because the benefits for prevention of cardiovascular events overweigh the glucose metabolism-related risks. 26,27 In Japan, no conclusion has been drawn regarding the effect of statins on glucose metabolism in the clinical setting, 28,29 but HbA 1c was not significantly affected after long-term (6-month) treatment with rosuvastatin in the present study. Given the benefits of statins for prevention of cardiovascular events, it may be crucial to continue statin therapy in patients with type 2 diabetes and dyslipidaemia, while monitoring glucose metabolism-related parameters, including HbA 1c .…”

Section: Discussioncontrasting

confidence: 67%

Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia

et al. 2014

View full text Add to dashboard Cite

Objective: To analyse the efficacy of low-dose rosuvastatin for treating hypo high-density lipoprotein (HDL) cholesterolaemia in patients with type 2 diabetes and dyslipidaemia. Methods: Patients with HDL-cholesterol (C) <40 mg/dl and triglycerides (TG) <400 mg/dl who were receiving treatment with lipid-lowering drugs other than rosuvastatin (or previously untreated with lipid-lowering drugs) and with low-density lipoprotein [LDL]-C !120 mg/dl were included. Patients were treated with 2.5 or 5 mg rosuvastatin orally, once daily, to achieve the target LDL-C level specified in Japanese guidelines. Changes in total cholesterol, HDL-C, TG, LDL-C, LDL-C/HDL-C and non-HDL-C at 3 and 6 months were prospectively analysed. Safety was evaluated by examining changes in hepatorenal function, glucose metabolism and creatine kinase. Results: Out of 49 patients, all lipid parameters other than TG were significantly improved at 3 and 6 months. At 3 months, 83.3% of patients had achieved the target LDL-C level. Among nonlipid parameters, no changes were observed except for estimated glomerular filtration rate, which was improved by þ 5.2% and þ 9.6% at 3 and 6 months, respectively. Conclusions: Low-dose rosuvastatin was effective in improving hypo-HDL cholesterolaemia and may have renoprotective effects.

show abstract

Section: Discussioncontrasting

confidence: 67%

Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia

et al. 2014

View full text Add to dashboard Cite

show abstract

“…38 A significantly greater decrease in serum LDL-C levels from the baseline occurred with rosuvastatin (−44.1%) than with pitavastatin (−36.9%, P , 0.01) in the rosuvastatin-pitavastatin group, and a significantly greater decrease with rosuvastatin (−44.7%) than with pitavastatin (−34.8%, P , 0.01) in the pitavastatin-rosuvastatin group. A significant reduction in serum LDL-C levels from the baseline was also observed with rosuvastatin (−44.6% at 12 weeks and −5.5% at 24 weeks) in the rosuvastatinrosuvastatin group and there were no significant differences between data at 12, and 24 weeks.…”

Section: Pitavastatin Vs Rosuvastatinmentioning

confidence: 85%

“…[24][25][26][27] Compared to other previously commercialized statins, pitavastatin proved to be as effective as atorvastatin in terms of the proportions of patients achieving the LDL-C goal, reductions in LDL-C, TC, and Tg, [26][27][28][29][30][31][32][33][34] but to be inferior to rosuvastatin in lowering LDL-C, and hs-CRP in patients with type 2 diabetes mellitus, 38 placing between atorvastatin and rosuvastatin in terms of effectiveness (Table 3). Moreover, compared to other statins, pitavastatin treatment was also associated with a significant greater increase in HDL-C levels ( Table 3).…”

Section: Discussionmentioning

confidence: 99%

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

Derosa¹,

Maffioli²

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

The progression of atherosclerosis and thus risk of cardiovascular disease is influenced by a variety of risk factors, including high levels of low-density lipoprotein cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C). Lowering the serum cholesterol level with diet or drug therapy slows the progression of angiographically documented coronary atherosclerosis in patients with arterial bypass grafts. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are the most potent pharmacologic agents for lowering total cholesterol (TC) and LDL-C. We conducted a review analyzing clinical efficacy and safety of pitavastatin, the latest statin to be commercialized, including the most important studies about pitavastatin published in the last ten years. Pitavastatin proved to be as effective as atorvastatin, and a little inferior to rosuvastatin in improving lipid profile, it also proved to be safe and well tolerated. Because of its positive pleiotropic effects on coronary plaque volume and fibro-fatty composition, pitavastatin could be a valid option for the treatment of hypercholesterolemia and combined dyslipidemia.

show abstract

“…Relatedly, we also found hyperlipidemia to be associated with Charcot foot. Treatment of CAD with 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors (i.e., “statins”) has also been described to have an anti-inflammatory effect [33, 34]. CAD has not been described in prior Charcot foot multivariate models [4, 5].…”

Section: Discussionmentioning

confidence: 99%

Data Mining for Identifying Novel Associations and Temporal Relationships with Charcot Foot

Munson

Wrobel

Holmes

et al. 2014

Journal of Diabetes Research

View full text Add to dashboard Cite

Introduction. Charcot foot is a rare and devastating complication of diabetes. While some risk factors are known, debate continues regarding etiology. Elucidating other associated disorders and their temporal occurrence could lead to a better understanding of its pathogenesis. We applied a large data mining approach to Charcot foot for elucidating novel associations. Methods. We conducted an association analysis using ICD-9 diagnosis codes for every patient in our health system (n = 1.6 million with 41.2 million time-stamped ICD-9 codes). For the current analysis, we focused on the 388 patients with Charcot foot (ICD-9 713.5). Results. We found 710 associations, 676 (95.2%) of which had a P value for the association less than 1.0 × 10−5 and 603 (84.9%) of which had an odds ratio > 5.0. There were 111 (15.6%) associations with a significant temporal relationship (P < 1.0 × 10−3). The three novel associations with the strongest temporal component were cardiac dysrhythmia, pulmonary eosinophilia, and volume depletion disorder. Conclusion. We identified novel associations with Charcot foot in the context of pathogenesis models that include neurotrophic, neurovascular, and microtraumatic factors mediated through inflammatory cytokines. Future work should focus on confirmatory analyses. These novel areas of investigation could lead to prevention or earlier diagnosis.

show abstract

A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes

Abstract: Therapy with both statins improved lipid profiles and reduced proinflammatory responses; however, 2.5 mg of ROS have a potent LDL-C-lowering and hsCRP-lowering effect compared with 2 mg of PIT in patients with diabetes.

Cited by 17 publications

References 30 publications

Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia

Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia

Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin

Data Mining for Identifying Novel Associations and Temporal Relationships with Charcot Foot

Contact Info

Product

Resources

About